Upstate seeks participants for national Alzheimer's study
Researchers at Upstate are seeking patients with mild to moderate Alzheimer's diseases for a national study of a promising new medication. "It may have the potential to modify the pace of the disease," neurologist Amy Sanders, MD, said of the drug, called T-817MA. Participants must be between the ages of 55 and 85 with a diagnosis of Alzheimer's disease and currently taking donepezil, or Aricept. Also in this interview, Sanders discusses what to expect as a normal part of cognitive aging.